Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727685 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTALDH1A1POLBMAPT | |
| SCHEMBL3071640 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTALDH1A1POLBMAPT | |
| SCHEMBL18496587 | 0.89 | HTT (0.55) | SMN1; SMN2HTTALDH1A1MAPTRAB9A | |
| SCHEMBL18285352 | 0.86 | HTT (0.50) | SMN1; SMN2HTTALDH1A1MAPTMEN1 | |
| SCHEMBL18496608 | 0.80 | HTT (0.45) | SMN1; SMN2HTTALDH1A1MAPTMEN1 | |
| SCHEMBL5507071 | 0.79 | ALDH1A1 (0.54) | SMN1; SMN2HTTALDH1A1POLBMAPT | |
| SCHEMBL18285290 | 0.78 | HTT (0.49) | SMN1; SMN2HTTALDH1A1POLBMAPT | |
| SCHEMBL29727653 | 0.78 | HTT (0.49) | SMN1; SMN2HTTALDH1A1POLBMAPT | |
| SCHEMBL18172342 | 0.77 | NPSR1 (0.39) | SMN1; SMN2HTTALDH1A1POLBMEN1 | |
| SCHEMBL13139938 | 0.77 | SMN1; SMN2 (0.85) | SMN1; SMN2HTTALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071451-B | Pyrazole compounds as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| EP-3464246-B1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-08 | — | — | EP | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | disclosed |
| EP-3464246-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-3286182-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. Hoffmann-La Roche AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017202896-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016169902-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119218-A1 | PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS | SLC1A1, SLC1A3, SLC1A2 | SMN1; SMN2 4697/4885HTT 1122/4885ALDH1A1 873/4885 |
| US-10457644-B2 | Pyrazol compounds as EAAT3 inhibitors | SLC1A1, SLC1A3, SLC1A2 | SMN1; SMN2 4697/4885HTT 1122/4885ALDH1A1 873/4885 |
| US-10577332-B2 | Tetrazole derivatives | MC2R, MC3R, GABRR3 | SMN1; SMN2 3684/4885HTT 394/4885ALDH1A1 1477/4885 |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | SMN1; SMN2 3964/4885HTT 530/4885ALDH1A1 765/4885 |
| US-10029989-B2 | Imidazole derivatives | DRD3, GABRR3, DRD4 | SMN1; SMN2 3964/4885HTT 530/4885ALDH1A1 765/4885 |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | MC2R, MC3R, GABRR3 | SMN1; SMN2 3684/4885HTT 394/4885ALDH1A1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.